Overview

SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate efficacy of drospirenone for dysmenorrhea.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Drospirenone
Ethinyl Estradiol